Assessing direct and indirect effects of pediatric influenza vaccination in Germany by individual-based simulations.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 04 2020
Historique:
pubmed: 28 10 2019
medline: 22 6 2021
entrez: 25 10 2019
Statut: ppublish

Résumé

Children have a high burden of influenza and play a central role in spreading influenza. Routinely vaccinating children against influenza may, thus, not only reduce their disease burden, but also that of the general population, including the elderly who frequently suffer severe complications. Using the published individual-based tool 4Flu, we simulated how pediatric vaccination would change infection incidence in Germany. Transmission of four influenza strains was simulated in 100,000 individuals with German demography and contact structure. After initialization with the recorded trivalent influenza vaccination coverage for 20 years (1997-2016), all vaccinations were switched to quadrivalent influenza vaccine (QIV). Scenarios where vaccination coverage of children (0.5-17-year-old) was increased from the current value (4.3%) to a maximum of 10-60% were compared to baseline with unchanged coverage, averaging results of 1,000 pairs of simulations over a 20-year evaluation period (2017-2036). Pediatric vaccination coverage of 10-60% annually prevented 218-1,732 (6.3-50.5%) infections in children, 204-1,961 (2.9-28.2%) in young adults and 95-868 (3.1-28.9%) in the elderly in a population of 100,000 inhabitants; overall, 34.1% of infections in the total population (3.7 million infections per year in Germany) can be prevented if 60% of all children are vaccinated annually. 4.4-4.6 vaccinations were needed to prevent one infection among children; 1.7-1.8 were needed to prevent one in the population. Enhanced pediatric vaccination prevents many infections in children and even more in young adults and the elderly.

Identifiants

pubmed: 31647348
doi: 10.1080/21645515.2019.1682843
pmc: PMC7227695
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-845

Références

Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876
pubmed: 20166072
BMC Infect Dis. 2017 Apr 26;17(1):308
pubmed: 28441935
J Infect Dis. 2004 Oct 15;190(8):1369-73
pubmed: 15378427
BMC Infect Dis. 2010 Jan 12;10:8
pubmed: 20067628
Pediatr Infect Dis J. 2013 Aug;32(8):881-8
pubmed: 23856713
JAMA. 2010 Mar 10;303(10):943-50
pubmed: 20215608
JAMA. 2000 Oct 4;284(13):1677-82
pubmed: 11015798
PLoS One. 2013;8(2):e57265
pubmed: 23468949
Vaccine. 2017 Jun 27;35(30):3789-3796
pubmed: 28558985
Vaccine. 2012 Feb 1;30(6):1208-24
pubmed: 22178725
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Euro Surveill. 2014 Feb 06;19(5):
pubmed: 24524235
Emerg Infect Dis. 2010 Aug;16(8):1265-72
pubmed: 20678321
BMC Infect Dis. 2016 Nov 7;16(1):646
pubmed: 27821137
BMC Infect Dis. 2014 Jul 03;14:365
pubmed: 24993051
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004879
pubmed: 22895945
Cochrane Database Syst Rev. 2014 Mar 13;(3):CD001269
pubmed: 24623315
PLoS One. 2011;6(9):e23955
pubmed: 21915270
Lancet Child Adolesc Health. 2018 May;2(5):338-349
pubmed: 30169267
PLoS One. 2015 Dec 14;10(12):e0144899
pubmed: 26658347
Pharmacoeconomics. 2016 Dec;34(12):1299-1308
pubmed: 27647004
Expert Rev Vaccines. 2014 Dec;13(12):1563-70
pubmed: 25138431
Vaccine. 2005 Feb 18;23(13):1540-8
pubmed: 15694506
BMC Infect Dis. 2014 Jan 22;14:40
pubmed: 24450996
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Epidemiol Infect. 2016 Aug;144(11):2295-305
pubmed: 27350234
N Engl J Med. 2001 Mar 22;344(12):889-96
pubmed: 11259722
Pediatr Infect Dis J. 2016 May;35(5):583-6
pubmed: 26910589
BMC Infect Dis. 2017 Apr 11;17(1):258
pubmed: 28399801
Vaccine. 2008 Sep 26;26(41):5321-30
pubmed: 18647634
Euro Surveill. 2015;20(39):
pubmed: 26537222

Auteurs

Ruprecht Schmidt-Ott (R)

GSK, Wavre, Belgium.

Daniel Molnar (D)

GSK, Wavre, Belgium.

Anastassia Anastassopoulou (A)

GSK, Munich, Germany.

Claudia Krumm (C)

GSK, Munich, Germany.

Rafik Bekkat-Berkani (R)

GSK, Philadelphia, PA, USA.

Philipp Henneke (P)

Center for Chronic Immunodeficiency and Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Markus Knuf (M)

Helios Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.

Markus Schwehm (M)

ExploSYS GmbH, Leinfelden-Echterdingen, Germany.

Martin Eichner (M)

Epimos GmbH, Dusslingen, Germany.
University of Tübingen, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH